Sarepta Therapeutics (NASDAQ:SRPT) Raised to “Hold” at Zacks Research

Sarepta Therapeutics (NASDAQ:SRPT) was upgraded by analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a note issued to investors on Wednesday,Zacks.com reports.

Other equities analysts also recently issued reports about the stock. Piper Sandler decreased their price target on shares of Sarepta Therapeutics from $23.00 to $20.00 and set a “neutral” rating on the stock in a research note on Thursday, July 9th. HC Wainwright reiterated a “buy” rating on shares of Sarepta Therapeutics in a report on Tuesday, July 28th. Wolfe Research raised shares of Sarepta Therapeutics from a “peer perform” rating to an “outperform” rating and set a $27.00 target price on the stock in a research note on Thursday, July 9th. Weiss Ratings cut Sarepta Therapeutics from a “sell (d+)” rating to a “sell (d)” rating in a report on Wednesday, August 5th. Finally, Wall Street Zen lowered Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Nine equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and five have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $25.06.

Sarepta Therapeutics Trading Up 0.2%

Shares of SRPT opened at $18.42 on Wednesday. Sarepta Therapeutics has a 52-week low of $14.68 and a 52-week high of $25.32. The company has a quick ratio of 2.62, a current ratio of 4.42 and a debt-to-equity ratio of 0.55. The firm’s fifty day moving average is $17.03 and its two-hundred day moving average is $18.40. The stock has a market cap of $1.95 billion, a PE ratio of -6.35, a price-to-earnings-growth ratio of 0.24 and a beta of 0.23.

Institutional Trading of Sarepta Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. AQR Capital Management LLC raised its position in shares of Sarepta Therapeutics by 214.2% during the 1st quarter. AQR Capital Management LLC now owns 5,385 shares of the biotechnology company’s stock valued at $344,000 after buying an additional 3,671 shares during the period. Great Lakes Advisors LLC purchased a new position in Sarepta Therapeutics in the first quarter worth approximately $224,000. Guggenheim Capital LLC increased its stake in Sarepta Therapeutics by 33.5% during the second quarter. Guggenheim Capital LLC now owns 45,790 shares of the biotechnology company’s stock worth $783,000 after acquiring an additional 11,497 shares during the last quarter. First Trust Advisors LP raised its position in Sarepta Therapeutics by 59.2% in the second quarter. First Trust Advisors LP now owns 627,561 shares of the biotechnology company’s stock valued at $10,731,000 after purchasing an additional 233,391 shares during the period. Finally, California Public Employees Retirement System raised its position in Sarepta Therapeutics by 7.1% in the second quarter. California Public Employees Retirement System now owns 115,340 shares of the biotechnology company’s stock valued at $1,972,000 after purchasing an additional 7,665 shares during the period. Institutional investors and hedge funds own 86.68% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.